Synergistic anti-inflammatory effect: Simvastatin and pioglitazone reduce inflammatory markers of plasma and epicardial adipose tissue of coronary patients with metabolic syndrome

Diabetology and Metabolic Syndrome

Volumn 6, Issue 1, 2014, Pages

  Grosso, Adriana Ferreira ^a   De Oliveira, Sérgio Ferreira ^a   Higuchi, Maria De Lourdes ^a   Favarato, Desidério ^a   Dallan, Luís Alberto De Oliveira ^a   Da Luz, Protásio Lemos ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Atherosclerosis; Epicardial adipose tissue; Inflammation; Pioglitazone; Simvastatin

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE; GELATINASE B; INTERLEUKIN 6; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; N(G),N(G) DIMETHYLARGININE; PIOGLITAZONE; RESISTIN; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; B LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CYTOKINE RELEASE; DRUG POTENTIATION; ELECTIVE SURGERY; EPICARDIAL ADIPOSE TISSUE; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; T LYMPHOCYTE; TRANSLUMINAL CORONARY ANGIOPLASTY; WAIST CIRCUMFERENCE;

EID: 84898729802     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-6-47     Document Type: Article

References (38)

1. Adipose tissue as an endocrine organ. Kershaw EE, Flier JS, J Clin Endocrinol Metab 2004 89 2548 2556 (Pubitemid 38766330)
2. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Moreno PR, Murcia AM, Palacios IF, Leon MN, Bernardi VH, Fuster V, Fallon JT, Circulation 2000 102 2180 2184
3. Inflammation and insulin resistance. Shoelson SE, Lee J, Goldfine AB, J Clin Invest 2006 116 1793 1801 (Pubitemid 44033299)
4. The metabolic syndrome: inflammation, diabetes mellitus and cardiovascular disease. Haffner SM, J Am Coll Cardiol 2006 97 3A 11A (Pubitemid 43139714)
5. Human epicardial adipose tissue is a source of inflammatory mediators. Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, Sarov-Blat L, O'Brien S, Keiper EA, Johnson AG, Martin J, Goldstein BJ, Shi Y, Circulation 2003 108 2460 2466 (Pubitemid 37444406)
6. Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Baker AR, Silva NF, Quinn DW, Harte AL, Pagano D, Bonser RS, Kumar S, McTernan PG, Cardiovasc Diabetol 2006 5 1 7
7. Macrophage-secreted factors induce adipocyte inflammation and insulin resistence. Permana PA, Menge C, Reaven PD, Biochem Biophys Res Commun 2006 341 507 514 (Pubitemid 43152134)
8. Enhanced inflammation in epicardial fat in patients with coronary artery disease. Hirata Y, Kurobe H, Akaike M, Chikugo F, Hori T, Bando Y, Nishio C, Higashida M, Nakaya Y, Kitagawa T, Sata M, Int Heart J 2011 52 139 142
9. The role of the adipocyte hormone adiponectin in cardiovascular disease. Hug C, Lodish HF, Curr Opin Pharmacol 2005 5 129 134 (Pubitemid 40378742)
10. Adiponectin expression in human epicardial adipose tissue in vivo is lower in patients with coronary artery disease. Iacobellis G, Pistilli D, Gucciardo M, Leonetti F, Miraldi F, Brancaccio G, Gallo P, di Gioia CR, Cytokine 2005 29 251 255 (Pubitemid 40320925)
11. Impact of partial volume effects on visceral adipose tissue quantification using MRI. Zhou A, Murillo H, Peng Q, J Magn Reson Imaging 2011 34 1452 1457
12. Ectopic fat storage in heart, blood vessels and kidneys in the pathogenesis of cardiovascular diseases. Montani JP, Carroll JF, Dwyer TM, Antic V, Yang Z, Dulloo AG, Int J Obes Relat Metab Disord 2004 28 58 S65
13. Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction. Iacobellis G, Assael F, Ribaudo MC, Zappaterreno A, Alessi G, Di Mario U, Leonetti F, Obes Res 2003 11 304 310 (Pubitemid 41127400)
14. Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. Iacobellis G, Ribaudo MC, Assael F, Vecci E, Tiberti C, Zappaterreno A, Di Mario U, Leonetti F, J Clin Endocrinol Metab 2003 88 5163 5168 (Pubitemid 37452712)
15. Drugs and lifestyle for the treatmen and prevention of coronary artery disease-comparative analysis of the scientific basis. Luz PL, Nishiyama M, Chagas AC, Braz J Med Biol Res 2011 44 973 991
16. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA, J Clin Endocrinol Metab 2004 89 4312 4319 (Pubitemid 39244431)
17. Pioglitazone and reductions in post-challenge glucose levels in patients with type 2 diabetes. Khan M, Murray FT, Karunaratne M, Perez A, Diabetes Obes Metab 2006 8 31 38
18. Pioglitazone reduces inflammatory responses of human adipocytes to factors secreted by monocytes/macrophages. Permana PA, Zhang W, Wabitsch M, Fischer-Posovszky P, Duckworth WC, Reaven PD, Am J Physiol Endocrinol Metab 2009 296 1076 E1084
19. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ, National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association, Circulation 2004 110 227 239 (Pubitemid 38924592)
20. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the insulin resistance atherosclerosis study. Hanley AJ, Karter AJ, Williams K, Festa A, D'Agostino RB Jr, Wagenknecht LE, Haffner SM, Circulation 2005 112 3713 3721 (Pubitemid 43739511)
21. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S, Circulation 2001 103 1933 1935 (Pubitemid 32322218)
22. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity c-reactive protein: the PIOSTAT study. Hanefeld M, Marx N, Pfützner A, Baurecht W, Lübben G, Karagiannis E, Stier U, Forst T, J Am Coll Cardiol 2007 49 290 297 (Pubitemid 46110954)
23. Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease. Forst T, Karagiannis E, Lübben G, Hohberg C, Schöndorf T, Dikta G, Drexler M, Morcos M, Dänschel W, Borchert M, Pfützner A, Atherosclerosis 2008 197 311 317 (Pubitemid 351273253)
24. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. Pfützner A, Marx N, Lübben G, Langenfeld M, Walcher D, Konrad T, Forst T, J Am Coll Cardiol 2005 45 1925 1931 (Pubitemid 40814110)
25. Insulin resistance and cardiovascular disease: the role of PPARγ activators beyond their anti-diabetic action. Walcher D, Marx N, Diab Vasc Dis Res 2004 1 76 81
26. Adipose tissue macrophages: their role in adipose tissue remodeling. Suganami T, Ogawa Y, J Leukoc Biol 2010 88 33 39
27. Inflammatory genes in epicardial fat contiguous with coronary atherosclerosis in the metabolic syndrome and type 2 diabetes: changes associated with pioglitazone. Sacks HS, Fain JN, Cheema P, Bahouth SW, Garrett E, Wolf RY, Wolford D, Samaha J, Diabetes Care 2011 34 730 733
28. Adiponectin secretion and response to pioglitazone is depot dependent in cutured human adipose tissue. Phillips SA, Ciaraldi TP, Oh DK, Savu MK, Henry RR, Am J Physiol Endocrinol Metab 2008 295 842 E850
29. Regulation of leptin release by troglitazone in human adipose tissue. Fain JN, Cowan GS Jr, Buffington C, Andersen RN, Pouncey L, Bahouth SW, Metabolism 2000 49 1485 1490
30. Increase plasma adiponectin in response to pioglitazone does not result from increased gene expression. Rasouli N, Yao-Borengasser A, Miles LM, Elbein SC, Kern PA, Am J Physiol Endocrinol Metab 2006 290 42 E46
31. Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Iacobelis G, Corradi D, Sharma AM, Nature 2005 2 536 543 (Pubitemid 41670345)
32. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H, Matsuzawa Y, Circulation 2003 107 671 674 (Pubitemid 36222590)
33. Epicardial adipose tissue adiponectin in patients with metabolic syndrome. Teijeira-Fernandez E, Eiras S, Shamagian LG, Cytokine 2011 54 185 190
34. Epicardial adipose tissue adiponectin expression is related to intracoronary adiponectin levels. Iacobellis G, di Gioia CR, Cotesta D, Petramala L, Travaglini C, De Santis V, Vitale D, Tritapepe L, Letizia C, Horm Metab Res 2009 41 3 227 231
35. Intracoronary adiponectin levels rapidly and significantly increase after coronary revascularization. Iacobellis G, Cotesta D, Petramala L, De Santis V, Vitale D, Tritapepe L, Letizia C, Int J Cardiol 2010 144 1 160 163
36. Ectopic lymphoid-organ development occurs through interleukin 7-mediated enhanced survival of lymphoid-tissue-inducer cells. Meier D, Bornmann C, Chappaz S, Schmutz S, Otten LA, Ceredig R, Acha-Orbea H, Finke D, Immunity 2007 26 643 654 (Pubitemid 46756355)
37. Mouse aorta smooth muscle cells differentiate into lymphoid tissue organizer-like cells on combined tumor necrosis factor receptor-1/lymphotoxin beta-receptor NF-kappaB signaling. Lötzer K, Döpping S, Connert S, Gräbner R, Spanbroek R, Lemser B, Beer M, Hildner M, Hehlgans T, van der Wall M, Mebius RE, Lovas A, Randolph GJ, Weih F, Habenicht AJ, Arterioscler Thromb Vasc Biol 2010 30 395 402
38. Lymphoid organ development: from ontogeny to neogenesis. Drayton DL, Liao S, Mounzer RH, Ruddle NH, Nat Immunol 2006 7 344 353